Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Panel to Mull Hernexeos 1st-Line Use, Rinvoq Alopecia Expansions
A Japanese health ministry panel will meet on October 21 to discuss a string of label expansions, including for Nippon Boehringer Ingelheim’s HER2 tyrosine kinase inhibitor Hernexeos (zongertinib) and AbbVie’s JAK inhibitor Rinvoq (upadacitinib). The Pharmaceutical Affairs Council’s Second Committee…
To read the full story
Related Article
- Pfizer Japan Files Tukysa Label Expansion in Breast, Biliary Tract Cancers
April 9, 2026
- Boehringer Files Hernexeos for First-Line NSCLC Use in Japan
March 23, 2026
- Stella Pharma Files Steboronine for Recurrent Meningioma
March 18, 2026
- Servier Japan Seeks First-Line Pancreatic Cancer Use for Onivyde
December 17, 2025
- AbbVie Japan Seeks Rinvoq’s Broader Label for Alopecia Areata
December 16, 2025
- Meiji Seeks Label Expansion for Laserphyrin in Cervical Intraepithelial Neoplasia
November 28, 2025
REGULATORY
- Provider-Payer Tug-of-War Takes Shape over FY2027 Drug Price Revision
October 8, 2026
- Imulrio Finally Set for NHI Listing after 296-Day Wait; Zero Rule Strikes Again
October 8, 2026
- Japan Panel to Mull Hernexeos 1st-Line Use, Rinvoq Alopecia Expansions
October 8, 2026
- SCARDA, Thai Vaccine Institute Link Up on KM Biologics’ Dengue Shot
October 7, 2026
- MHLW Opens Applications for Innovation Fund’s Ecosystem Program
October 7, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…